A Phase 1 interventional study of FT-003 in Diabetic Macular Edema, sponsored by Frontera Therapeutics. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-23.
Sponsored by Frontera Therapeutics · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 72 studies in Macular Edema with a site in China — 18 open to participants now, 22 under way, 4 of them phase 3. Macular Edema · China.
Among the 72 studies in Macular Edema with a site in China, this one is the 60th largest by planned enrollment of the 65 interventional ones that give a count, is one of 11 that started in 2023, is one of 9 in phase 1, reaches primary completion later than 5 of the 21 other live ones, and was the 50th registered.
759 studies on the registry are indexed under Macular Edema; 66 are open to participants now.
Browse Macular Edema studies →18 of the 72 studies in Macular Edema with a site in China are open now. Recruiting first, the newest first:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18+
First Affiliated Hospital of Chongqing Medical University · Sites in China
Ages 18–80
Boehringer Ingelheim · Sites in China, United States, Czechia and 6 more countries
Ages 18+
Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm) · Sites in China, United States, Australia
Ages 18–65
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
72 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 12 · Phase 3 26 · Phase 4 9
First in 2003; this study’s year is marked. 11 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 18 is below the median of 56 across 587 interventional studies indexed under Macular Edema.
Median enrollment 140 across the 65 interventional studies, 110 across the 7 observational. Of the 38 that completed or were terminated, 13 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 72 have an industry lead sponsor. The 10 most frequent:
Frontera Therapeutics is the lead sponsor of 7 studies on the registry; 7 are open to participants now.
Frontera Therapeutics has 2 studies filed under Macular Edema — fewer than ten, so there is no comparison to draw.
5 of the studies in Macular Edema with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07515079Phase 3Bio-Thera SolutionsEfficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Diabetic Macular Edema | 2027-04-30 |
| NCT07019896Peking Union Medical College HospitalMinimal Vitrectomy Surgery for Epiretinal Membrane | 2026-11-30 |
| NCT06548568AbbVieA Real-world Study to Assess Safety of OZURDEX® (Dexamethasone Intravitreal Implant) in Adult Participants With Diabetic Macular Edema in China | 2027-04 |
| NCT07133438First Affiliated Hospital of Chongqing Medical UniversityMecobalamin Combined With Anti-VEGF Intravitreal Injection for Retinal Vein Occlusion Treatment | 2027-05-31 |
| NCT07362927Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineSafety and Efficacy Evaluation of LX111 Gene Therapy in DME Patients | 2027-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 72 studies in Macular Edema with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
FT-003 is a gene therapy product developed for the treatment of central involvement diabetic macular edema (CI-DME). Diabetic retinopathy is one of the most common microvascular complications of diabetes mellitus, and diabetic macular edema is the main cause of vision loss in patients with diabetic retinopathy. In the latest guidelines, anti-VEGF therapy is preferred for CI-DME. Administration of FT-003 has the potential to treat CI-DME by providing intraocular protein which is durable expressed in therapeutic level. FT-003 is designed to reduce the current treatment burden which often results in undertreatment and vision loss in patients with CI-DME receiving anti-VEGF therapy in clinical practice.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Low dose of FT-003
Genetic: FT-003
Mid dose of FT-003
Genetic: FT-003
High dose of FT-003
Genetic: FT-003
Administration via intraocular injection
Safety and tolerability after FT-003 injection
Incidence and severity of AE (Common Terminology Criteria for Adverse Events 5.0)
Time frame: Whthin 52 weeks after administration
Preliminary effectiveness after FT-003 injection
Changes in best-corrected visual acuity (BCVA) of the studied eye from baseline
Time frame: Whthin 52 weeks after administration
Plan to share: No
No publications or documents are linked to this record.
Started May 2023 (actual). Primary completion is estimated for May 2025, 23 months after the start.
Of 25 phase 1 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 51. This study's planned 23 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Frontera Therapeutics